Mechanisms of cellular drug resistance and strategies to overcome it

Biomaterials for Delivery and Targeting of Proteins and Nucleic Acids

Volumn , Issue , 2004, Pages 461-492

  Minko, Tamara ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85056319683     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (44)

1. Masia Canuto, M., and Gutierrez Rodero, F., Antifungal drug resistance to azoles and polyenes. Lancet Infect. Dis., 2002; 2: 550-563.
2. Westerman, D. A., Speed, B. R., and Prince, H. M., Fatal disseminated infection by Scedosporium prolificans during induction therapy for acute leukemia: a case report and literature review. Pathology, 1999; 31: 393-394.
3. Pakunlu, R. I., Cook, T. J., and Minko, T., Simultaneous modulation of multidrug resistance and antiapoptotic cellular defense by MDR1 and BCL-2 targeted antisense oligonucleotides enhances the anticancer efficacy of doxorubicin. Pharm. Res., 2003; 20: 351-359.
4. Dharap, S. S., and Minko, T., Targeted proapoptotic LHRH-BH3 peptide. Pharm. Res., 2003; 20: 889-896.
5. Minko, T., Kopeckova, P., Pozharov, V., and Kopecek, J., HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J. Control Release, 1998; 54: 223-233.
6. Minko, T., Kopeckova, P., and Kopecek, J., Chronic exposure to HPMA copolymer-bound adriamycin does not induce multidrug resistance in a human ovarian carcinoma cell line. J. Control Release, 1999; 59: 133-148.
7. Nikaido, H., Prevention of drug access to bacterial targets: permeability barriers and active efflux. Science, 1994; 264: 382-388.
8. Roepe, P. D., What is the precise role of human MDR 1 protein in chemotherapeutic drug resistance? Curr. Pharm. Des., 2000; 6: 241-260.
9. van Veen, H. W., and Konings, W. N., The ABC family of multidrug transporters in microorganisms. Biochim. Biophys. Acta, 1998; 1365: 31-36.
10. Ueda, K., Yoshida, A., and Amachi, T., Recent progress in P-glycoprotein research. Anticancer. Drug Des., 1999; 14: 115-121.
11. Szakacs, G., Jakab, K., Antal, F., and Sarkadi, B., Diagnostics of multidrug resistance in cancer. Pathol. Oncol. Res., 1998; 4: 251-257.
12. Minko, T., Kopeckova, P., and Kopecek, J., Efficacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma. Int. J. Cancer, 2000; 86: 108-117.
13. Minko, T., Kopeckova, P., and Kopecek, J., Comparison of the anticancer effect of free and HPMA copolymer-bound adriamycin in human ovarian carcinoma cells. Pharm. Res., 1999; 16: 986-996.
14. Gross, A., McDonnell, J. M., and Korsmeyer, S. J., BCL-2 family members and the mitochondria in apoptosis. Genes Dev., 1999; 13: 1899-1911.
15. Reed, J. C., Dysregulation of apoptosis in cancer. J. Clin. Oncol., 1999; 17: 2941-2953.
16. Lowe, S. W., and Lin, A. W., Apoptosis in cancer. Carcinogenesis, 2000; 21: 485-495.
17. Oltvai, Z. N., Milliman, C. L., and Korsmeyer, S. J., Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell, 1993; 74: 609-619.
18. Minko, T., Kopeckova, P., and Kopecek, J., Preliminary evaluation of caspases-dependent apoptosis signaling pathways of free and HPMA copolymer-bound doxorubicin in human ovarian carcinoma cells. J. Control Release, 2001; 71: 227-237.
19. Minko, T., Dharap, S. S., and Fabbricatore, A. T., Enhancing the efficacy of chemotherapeutic drugs by the suppression of antiapoptotic cellular defense. Cancer Detect. Prev., 2003; 27: 193-202.
20. Dharap, S. S. et al., Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides. J. Control Release, 2003; 91: 61-73.
21. Minko, T., Drug targeting to the colon with lectins and neoglycoconjugates. Adv. Drug Deliv. Rev., 2004; 56: 491-509.
22. Philip, T., and Biron, P., High-dose chemotherapy and autologous bone marrow transplantation in diffuse intermediate- and high-grade non-Hodgkin lymphoma. Crit. Rev. Oncol. Hematol., 2002; 41: 213-223.
23. Rodriguez, T. E., and Stiff, P. J., Current treatment results of allogeneic bone marrow transplantation for acute myeloid and lymphoid leukemia. Curr. Hematol. Rep., 2003; 2: 295-301.
24. D’Hondt, V., Symann, M., and Machiels, J. P., Chemoprotection and selection by chemotherapy of multidrug resistance-associated protein-1 (MRP1) transduced cells. Curr. Gene Ther., 2001; 1: 359-366.
25. Fruehauf, S. et al., Gene therapy for sarcoma. Cells Tissues Organs, 2002; 172: 133-144.
26. Krishna, R., and Mayer, L. D., Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci., 2000; 11: 265-283.
27. Fojo, T., and Bates, S., Strategies for reversing drug resistance. Oncogene, 2003; 22: 7512-7523.
28. Kawase, M., and Motohashi, N., New multidrug resistance reversal agents. Curr. Drug. Targets, 2003; 4: 31-43.
29. 0 end region of MDR1 gene decreases resistance to doxorubicin of human adenocarcinoma-resistant cells. Anticancer Res., 1992; 12: 1431-1438.
30. Motomura, S. et al., Inhibition of P-glycoprotein and recovery of drug sensitivity of human acute leukemic blast cells by multidrug resistance gene (mdr1) antisense oligonucleotides. Blood, 1998; 91: 3163-3171.
31. Torchilin, V. P., Khaw, B. A., and Weissig, V., Intracellular targets for DNA delivery: nuclei and mitochondria. Somat. Cell Mol. Genet., 2002; 27: 49-64.
32. Kopecek, J., Kopeckova, P., Minko, T., and Lu, Z., HPMA copolymeranticancer drug conjugates: design, activity, and mechanism of action. Eur. J. Pharm. Biopharm., 2000; 50: 61-81.
33. Kopecek, J. et al., Water soluble polymers in tumor targeted delivery. J. Control Release, 2001; 74: 147-158.
34. Matsumura, Y., and Maeda, H., A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res., 1986; 46: 6387-6392.
35. Maeda, H., Seymour, L. W., and Miyamoto, Y., Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjug. Chem., 1992; 3: 351-362.
36. Noguchi, Y. et al., Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn J. Cancer Res., 1998; 89: 307-314.
37. Minko, T. et al., The influence of cytotoxicity of macromolecules and of VEGF gene modulated vascular permeability on the enhanced permeability and retention effect in resistant solid tumors. Pharm. Res., 2000; 17: 505-514.
38. Minko, T. et al., Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells. Cancer Chemother. Pharmacol., 2002; 50: 143-150.
39. Minko, T., Dharap, S. S., Pakunlu, R. I., and Wang, Y. H., Molecular targeting of drug delivery systems to cancer. Curr. Drug Targets, 2004; 5: 389-406.
40. Nieth, C., Priebsch, A., Stege, A., and Lage, H., Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). FEBS Lett, 2003; 545: 144-150.
41. Wu, H., Hait, W. N., and Yang, J. M., Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res., 2003; 63: 1515-1519.
42. Cosulich, S. C. et al., Regulation of apoptosis by BH3 domains in a cell-free system. Curr. Biol., 1997; 7: 913-920.
43. Holinger, E. P., Chittenden, T., and Lutz, R. J., Bak BH3 peptides antagonize Bcl-xL function and induce apoptosis through cytochrome c-independent activation of caspases. J. Biol. Chem., 1999; 274: 13298-13304.
44. Lutz, R. J., Role of the BH3 (Bcl-2 homology 3) domain in the regulation of apoptosis and Bcl-2-related proteins. Biochem. Soc. Trans., 2000; 28: 51-56.